1.
Neurosci Behav Physiol
; 39(2): 193-7, 2009 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19140003
Assuntos
Transtornos Cerebrovasculares/complicações , Transtornos Cognitivos/etiologia , Fármacos Neuroprotetores/uso terapêutico , Piracetam/uso terapêutico , Idoso , Assistência Ambulatorial , Doença Crônica , Progressão da Doença , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Testes Neuropsicológicos , Índice de Gravidade de Doença
2.
Neurosci Behav Physiol
; 38(9): 933-6, 2008 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18975095
RESUMO
Despite the significant symptomatic effects of levodopa, stable 24-h treatment responses are in the vast majority of patients replaced 2-3 years from the start of treatment by oscillations in motor symptoms (fluctuation, dyskinesia), amelioration of which requires addition of constant (physiological) stimulation of postsynaptic dopamine receptors. To some extent this is provided by Stalevo, which contains levodopa and two enzyme inhibitors: the DDC inhibitor carbidopa and the COMT inhibitor entacapone. The results obtained in the present study demonstrated the advantages of Stalevo over traditional agents in patients with the "wearing off" and "on-off" phenomena.